Celcuity Inc. (CELC) saw its stock climb nearly 16% on Monday, building on momentum from late Friday when the Minneapolis-based biotech announced positive results from a pivotal Phase 3 trial of its lead candidate, gedatolisib. The drug met its primary endpoint in patients with PIK3CA-mutant, HR+/HER2- advanced breast cancer, a group that represents about 40% of HR+/HER2- cases.
This new data opens the door for an expanded label for gedatolisib. The company plans to submit the results to the U.S. Food and Drug Administration (FDA) as a supplemental New Drug Application, aiming to secure approval for this additional patient population. The stock was trading at $145.54 in the afternoon, up $19.89, with the market capitalization hovering near $6.9 billion. Earlier in the session, shares hit an intraday high of $165.
The FDA decision on the initial application for gedatolisib in HR+/HER2-/PIK3CA wild-type advanced breast cancer is scheduled for July 17, 2026, under priority review. The new data targets the opposite genetic profile—mutant PIK3CA—potentially doubling the drug's addressable market if approved.
Phase 3 VIKTORIA-1 Trial Details
The Phase 3 VIKTORIA-1 trial evaluated gedatolisib in combination with fulvestrant, with or without palbociclib, in patients whose cancer had progressed after prior treatment with a CDK4/6 inhibitor and an aromatase inhibitor. The primary endpoint was progression-free survival (PFS), measuring the time until disease worsening or death.
Celcuity reported that the three-drug regimen (gedatolisib + fulvestrant + palbociclib) outperformed the control arm of alpelisib (Novartis' Piqray) plus fulvestrant. Additionally, the two-drug combination of gedatolisib and fulvestrant also showed superiority over alpelisib plus fulvestrant on a secondary endpoint. Both arms were generally well tolerated, with no unexpected safety signals, according to the company's 8-K filing.
Dr. Sara Hurvitz, co-principal investigator and oncologist at Fred Hutch Cancer Center and the University of Washington, noted that patients in this PIK3CA-mutant subgroup typically derive only modest benefit from existing PI3K-alpha or AKT inhibitors. Celcuity's Chief Medical Officer, Igor Gorbatchevsky, emphasized that the data across both mutant and wild-type cohorts suggest gedatolisib has the potential to improve the standard of care regardless of PIK3CA status.
Competitive Landscape and Analyst Reactions
Gedatolisib targets the PI3K/AKT/mTOR pathway, a key survival mechanism for cancer cells. This places it in direct competition with established drugs like Novartis' Piqray, Roche's Itovebi, and AstraZeneca's Truqap. The market closely watched the two-drug data, which analysts found particularly compelling.
Jefferies' Maury Raycroft called the doublet outcome "particularly notable," while Leerink Partners' Andrew Berens commented that the late-breaking oral presentation at the upcoming American Society of Clinical Oncology (ASCO) meeting "bodes well for the magnitude of benefit," as reported by BioPharma Dive. Stifel's Stephen Willey raised his price target to $150 from $125, calling the ASCO slot the "real surprise." Guggenheim's Brad Canino increased his target to $165 from $135, and Craig-Hallum's Chase Knickerbocker lifted his to $189 from $141.
Despite the optimism, the results are top-line only, and median PFS numbers have not yet been disclosed. Celcuity cautioned in its 8-K that the analysis is ongoing and may change with further review. Risks also include FDA review timing, potential approval, market adoption, and competition.
Financial Position and Upcoming Catalysts
Celcuity remains a clinical-stage company with no approved products or revenue. It reported a net loss of $177.0 million in 2025, but ended the year with $165.7 million in cash and cash equivalents, plus $275.8 million in short-term investments, providing a runway through key milestones.
Investors have two major events to watch: on June 2, Celcuity will present detailed VIKTORIA-1 mutant-cohort results in a late-breaking oral session at the ASCO meeting in Chicago. Then, on July 17, the FDA's target action date will determine whether gedatolisib receives its first approval in the wild-type indication. If successful, this could mark the company's transition from a clinical-stage biotech to a commercial-stage player.
